birtamimab
prothena
['birtamimab']
data from post-hoc analysis of vital makes me cautiously optimistic about anti-fibril therapy in stage iiib al. os, qol &amp; 6 minute walk test mirror each other!! affirm-al and cael trials will definitely prove if this holds up with dara-cybord induction #ash22 
Hematologist/Cancer Doctor/Clinical Researcher @ColumbiaCancer 
#Myeloma #Amyloidosis
Asst. Prof @ColumbiaMed
Host @BloodCancerTalk
COI: https://t.co/du0rVN9gca